Aligos Therapeutics Files 8-K Report
Ticker: ALGS · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Aligos Therapeutics filed an 8-K, but the details are scarce.
AI Summary
On September 3, 2024, Aligos Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific details regarding the nature of these events, any associated financial figures, or definitive dates beyond the filing date were provided in the excerpt.
Why It Matters
This filing signals that Aligos Therapeutics has made a regulatory submission to the SEC, which may contain material information for investors. However, the provided excerpt lacks specific details to ascertain the immediate impact.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediately discernible negative or positive financial or operational news in the provided text.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- September 3, 2024 (date) — Date of earliest event reported
- 001-39617 (other) — Commission File Number
- 94080 (other) — Zip Code
FAQ
What specific event triggered this 8-K filing by Aligos Therapeutics?
The provided excerpt does not specify the exact event, only that it falls under 'Other Events' and was reported on September 3, 2024.
Does the filing mention any financial transactions or agreements?
The excerpt does not contain any information about financial transactions or agreements.
Are there any updates on Aligos Therapeutics' clinical trials or drug development pipeline?
This specific filing excerpt does not provide any details regarding clinical trials or drug development.
What is the significance of the 'Other Events' category in an 8-K filing?
The 'Other Events' category is used for material events that do not fit into the other specific categories of an 8-K report.
When was the report filed with the SEC?
The report was filed as of date September 5, 2024, with the earliest event reported on September 3, 2024.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-09-05 16:06:55
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
- $1.00 — iled to maintain a minimum bid price of $1.00 or more for 30 consecutive business day
Filing Documents
- d857897d8k.htm (8-K) — 23KB
- 0001193125-24-214188.txt ( ) — 145KB
- algs-20240903.xsd (EX-101.SCH) — 3KB
- algs-20240903_lab.xml (EX-101.LAB) — 18KB
- algs-20240903_pre.xml (EX-101.PRE) — 11KB
- d857897d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: September 5, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer